Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cinclus Pharma Holding AB ( (SE:CINPHA) ).
Cinclus Pharma said its development program is centered on linaprazan glurate, designed to offer superior acid control and improved healing of erosive GERD compared with current proton pump inhibitors for patients with more severe disease. The company has documented safety and efficacy for linaprazan-based therapies in more than 30 phase I and two phase II studies, and launched its first Phase III trial in 2025 to pursue approval in major Western markets.
The company reported that new FDA guidance now makes a single adequate and well-controlled pivotal study, supported by additional evidence, the standard for U.S. drug approvals, even in common diseases. This confirms that Cinclus Pharma’s ongoing Phase III program for linaprazan glurate in erosive GERD, including an initial European healing study and a second transatlantic healing and maintenance study, should be sufficient for regulatory submissions in both the US and Europe, potentially accelerating its path to market and reinforcing its position in next-generation GERD treatment.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Its lead candidate, linaprazan glurate, a next-generation potassium-competitive acid blocker originally derived from AstraZeneca’s linaprazan, targets severe erosive gastroesophageal reflux disease in a market of millions of patients in the US and Europe.
Average Trading Volume: 42,242
Technical Sentiment Signal: Sell
Current Market Cap: SEK786.5M
For detailed information about CINPHA stock, go to TipRanks’ Stock Analysis page.